Home > Search Results

Results: 1 to 20 of 149

Rituximab for eradicating inhibitors in people with acquired haemophilia A

We reviewed the evidence about the effect of rituximab for treating people with acquired haemophilia A.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Rituximab for the treatment of thyroid eye disease

Thyroid eye disease affects 50% of patients with the autoimmune condition, Graves' disease. Symptoms include eye pain, redness, swelling, protrusion (proptosis), double vision, and in severe cases, reduction in vision. Currently treatment options include steroids and radiotherapy, but relapses are common. Surgery is reserved for severe cases. Rituximab is a medication given by intravenous infusion which has been shown to benefit patients with other autoimmune conditions like rheumatoid arthritis. This review was designed to investigate whether rituximab is effective and safe as a treatment option for patients with thyroid eye disease. There is a lack of evidence from randomised controlled trials to support the use of rituximab for thyroid eye disease. Rigorous studies looking at patients with active thyroid eye disease, comparing rituximab treatment with either steroids or placebo, need to be conducted in order to answer this question.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2013

Although the addition of the anti‐CD20 monoclonal antibody rituximab to chemotherapy (R‐chemo) has been shown to improve response rates and progression‐free survival in patients with indolent or mantle cell lymphoma, the efficacy of R‐chemo with respect to overall survival is unclear.

Study design: Meta‐analysis of seven randomised controlled trials involving 1943 patients.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2008

Rituximab as maintenance therapy for patients with follicular lymphoma

Follicular lymphoma is a B‐cell lymphoma characterised by an initial response to treatment that is usually followed by relapse and progression. Most patients present with advanced disease that cannot be cured. Lymphoma B‐cells express CD20. Rituximab, a monoclonal anti‐CD20 antibody, is expected to be active against cells that express CD20. Compared to chemotherapy alone, rituximab in combination with chemotherapy improves overall survival when used for induction therapy (treatment designed as a first step toward reducing the number of cancer cells) for patients with newly diagnosed or relapsed indolent lymphoma. Clinical trials that have shown improved event‐free survival were inconsistent regarding overall (all‐cause) survival. We aimed to evaluate the effects of maintenance therapy with rituximab on overall survival in patients with follicular lymphoma.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2009

The use of the monoclonal antibody rituximab in patients with relapsing remitting multiple sclerosis (RRMS)

This is an update of the Cochrane review "Rituximab for relapsing‐remitting multiple sclerosis" (first published in The Cochrane Library 2011, Issue 12).

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2014

Rituximab for rheumatoid arthritis

‐ reduced joint damage as seen on the x‐ray.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2014

Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical and Cost-effectiveness [Internet]

The purpose of this report is to retrieve and review existing evidence for the clinical effectiveness, safety, and cost-effectiveness of rituximab (RTX) treatments, beyond the initial course, for the maintenance of remission in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) patients.

Rapid Response Report: Summery With Critical Appraisal - Canadian Agency for Drugs and Technologies in Health.

Version: January 28, 2015
Show search results within this document

Role of rituximab in the treatment of postpartum acquired haemophilia A: a systematic review of the literature

Bibliographic details: Bonfanti C, Crestani S, Frattini F, Sissa C, Franchini M.  Role of rituximab in the treatment of postpartum acquired haemophilia A: a systematic review of the literature. Blood Transfusion 2014: epub25545867

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation

Rheumatoid arthritis (RA) is an inflammatory condition that typically causes a symmetrical chronic arthritis. Timely use of disease-modifying antirheumatic drugs (DMARDs) is an essential aspect of disease management, but many patients may not respond even when conventional agents are used optimally.

Health Technology Assessment - NIHR Journals Library.

Version: March 2011
Show search results within this document

Rituximab for treating inhibitors in people with inherited severe hemophilia

We reviewed the evidence available to see if rituximab is effective and safe when treating clotting factor inhibitors in people with severe hemophilia. This is an update of a previously published Cochrane Review.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2017

Rituximab (MabThera®) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation

Rituximab, a novel immunotherapeutic agent, is proposed for first-line use, in its currently licensed indication for stage II-IV diffuse large B-cell lymphoma, in conjunction with the CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy regime.

NIHR Health Technology Assessment programme: Executive Summaries - NIHR Journals Library.

Version: 2004

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Rheumatoid arthritis (RA) is a common inflammatory condition that typically causes a symmetrical chronic arthritis that causes joint pain, swelling and in some cases a systemic illness. The cause of RA is unknown, but important genetic influences are recognised. The goal of treatment is to achieve remission if patients present with early disease. In later disease, key goals are to control pain and inflammation and thereby reduce functional limitations and the risk of permanent joint damage.

NIHR Health Technology Assessment programme: Executive Summaries - NIHR Journals Library.

Version: 2011

Rituximab combined with routine chemotherapy in treatment of B-cell lymphoma: a meta analysis of randomized controlled trials

Bibliographic details: Tian YP, Yao YZ, Peng F.  Rituximab combined with routine chemotherapy in treatment of B-cell lymphoma: a meta analysis of randomized controlled trials. Chinese Journal of Cancer Biotherapy 2011; 18(1): 63-69

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

A meta-analysis on rituximab combined CHOP chemotherapy for non-Hodgkin lymphoma in China

OBJECTIVE: To evaluate the curative effect of Rituximab combined CHOP chemotherapy in patients with non-Hodgkin lymphoma in China.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis

Rituximab, a monoclonal antibody against the pan B-cell antigen CD20, has been successfully used in both adults and children for the management of malignant and non-malignant immune-mediated disorders including acquired haemophilia. On the basis of this positive experience, a number of investigators have recently used this agent in patients with congenital haemophilia and inhibitors refractory to first-line treatments. After a careful electronic and hand search, we have collected 29 studies that included 49 cases. A durable complete remission was obtained in 53% of the cases and no severe adverse events related to rituximab were recorded. A multivariate analysis applied to individual patients' data identified the diagnosis of a mild/moderate haemophilia and the concomitant treatment with factor VIII concentrates and immunosuppression agents as covariates associated with an increased response to rituximab. Large prospective randomized studies with an adequate follow-up are needed to confirm these preliminary findings.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis

Rituximab maintenance therapy has emerged as an effective treatment for low-grade lymphomas. No major acute or cumulative toxicities were observed in patients receiving rituximab maintenance therapy compared with observation arms in clinical trials. However, B-cells are completely depleted throughout the maintenance period and even longer, which may render patients at high risk for infections. Several infections related to rituximab have been reported in the literature. Yet it is not clear whether rituximab maintenance therapy increases the infectious complications or not. To further investigate this topic, we have performed a systematic review and meta-analysis of randomised controlled trials (RCT). The meta-analysis of five RCTs showed that rituximab maintenance therapy significantly increased the relative risk of both infection and neutropenia in patients with lymphoma. On the basis of the available evidence, patients who received rituximab maintenance treatment have higher risk of neutropenia and infection than those who did not. Previously treated patients particularly with fludarabine containing regimens are more susceptible to infectious complications and require extended vigilance.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis

OBJECTIVE: To identify if rheumatoid factor (RF) is predictor of response to rituximab (RTX), abatacept (ABT), and tocilizumab (TCZ) in rheumatoid arthritis (RA).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Rituximab for troublesome cases of childhood nephrotic syndrome

Nephrotic syndrome (NS) is the most common glomerular disease of childhood. Steroid-dependent and steroid-resistant nephrotic syndrome present challenges in their pharmaceutical management; patients may need several immunosuppressive medication for optimum control, each of which medication has its own safety profile. Rituximab (RTX) is a monoclonal antibody that targets B cells and has been used successfully for management of lymphoma and rheumatoid arthritis. Recent clinical studies showed that rituximab may be an efficacious and safe alternative for the treatment of complicated nephrotic syndrome. In this review article, we aim to review the efficacy and safety of RTX therapy in nephrotic syndrome. We reviewed the literature pertaining to this topic by searching for relevant studies on PubMed and Medline using specific keywords. The initial search yielded 452 articles. These articles were then examined to ensure their relevance to the topic of research. We focused on multicenter randomized controlled trials with relatively large numbers of patients. A total of 29 articles were finally identified and will be summarized in this review. The majority of clinical studies of RTX in complicated pediatric NS showed that rituximab is effective in approximately 80% of patients with steroid-dependent NS, as it decreases the number of relapses and steroid dosage. However, RTX is less effective at achieving remission in steroid-resistant NS. RTX use was generally safe, and most side effects were transient and infusion-related. More randomized, double-blinded clinical studies are needed to assess the role of RTX in children with nephrotic syndrome.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Biologics for rheumatoid arthritis: an overview of Cochrane reviews

This summary of a Cochrane review presents what we know from research about the effect of biologics on Rheumatoid Arthritis (RA).

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2013

The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature

The increase of fludarabine-resistant chronic lymphocytic leukemia (CLL) presents a new treatment challenge. The aim of this review is to evaluate the efficacy and safety of rituximab for patients with fludarabine-refractory CLL. Medline, Embase, The Cochrane Library and selected conference proceedings were searched. Seventeen relevant publications reporting stratified data were identified. Treatments included: rituximab in combination with etanercept, alemtuzumab, bendamustine or methylprednisolone alone, with fludarabine and cyclophosphamide (FCR), with oxaliplatin as well as fludarabine and cytarabine, with cyclophosphamide as well as fludarabine and alemtuzumab (CFAR), and with cytarabine, cisplatinum and dexamethasone (DHAP). One study evaluated rituximab with granulocyte-macrophage colony-stimulating factor in combination with alternating cyclophosphamide, liposomal daunorubicin, vincristine, dexamethasone and methotrexate plus Ara-C. One study evaluated rituximab as monotherapy. Of the nine studies considering overall response, eight reported rates above 50% (four reported rates above 75%). Median overall survival was 37 months for FCR, 11 months for CFAR, 20 months for rituximab with methylprednisolone, 30 months for rituximab with alemtuzumab and 44 months for an FCR/CFAR mixed treatment. The identified studies indicate that regimens containing rituximab may be highly efficacious in the fludarabine-refractory CLL setting. Nevertheless, further research is needed to facilitate the choice of treatment for the clinician.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Systematic Reviews in PubMed

See all (687)...

Systematic Review Methods in PubMed

See all (6)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...